BioStem Technologies Files S-1 for U.S. IPO
BioStem Technologies, Inc. filed an S-1 registration statement with the SEC on October 2, 2026, initiating its IPO process targeting NASDAQ or NYSE listing. The filing does not disclose expected offering size or underwriters, but marks the formal commencement of its U.S. public listing journey.
51CFO view：For pre-IPO companies, the S-1 requires CFOs to demonstrate direct SEC reporting experience and SOX 404 internal control implementation history—especially critical for biotech firms needing ASC 730-compliant R&D capitalization policies validated by auditors.
BioStem Technologies, Inc. filed an S-1 registration statement with the SEC on October 2, 2026, initiating its IPO process targeting NASDAQ or NYSE listing. The filing does not disclose expected offering size or underwriters, but marks the formal commencement of its U.S. public listing journey.
Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
What to do 18 months before filing
Financial readiness: audit basis, internal control, equity restatement.
Read →